Doseology Sciences Inc.
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, including tinctures. It sells its products online through doseology.com and e-commerce platforms, as well as through various retail chains and distribut… Read more
Doseology Sciences Inc. (DOSEF) - Net Assets
Latest net assets as of September 2025: $1.69 Million USD
Based on the latest financial reports, Doseology Sciences Inc. (DOSEF) has net assets worth $1.69 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.79 Million) and total liabilities ($107.03K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.69 Million |
| % of Total Assets | 94.03% |
| Annual Growth Rate | 5.47% |
| 5-Year Change | -45.75% |
| 10-Year Change | N/A |
| Growth Volatility | 66.92 |
Doseology Sciences Inc. - Net Assets Trend (2020–2025)
This chart illustrates how Doseology Sciences Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Doseology Sciences Inc. (2020–2025)
The table below shows the annual net assets of Doseology Sciences Inc. from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $1.40 Million | +37.06% |
| 2024-06-30 | $1.02 Million | -21.54% |
| 2023-06-30 | $1.30 Million | -56.65% |
| 2022-06-30 | $3.00 Million | +16.35% |
| 2021-06-30 | $2.58 Million | +140.58% |
| 2020-06-30 | $1.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Doseology Sciences Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 613505800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $7.96 Million | 569.83% |
| Total Equity | $1.40 Million | 100.00% |
Doseology Sciences Inc. Competitors by Market Cap
The table below lists competitors of Doseology Sciences Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ONTRAK INC.PRF.SER.A DL25
F:HY1
|
$915.43 |
|
NASCON ALLIED INDUSTRIES PLC
XNSA:NASCON
|
$915.61 |
|
CANDENTE GOLD (I97.SG)
STU:I97
|
$917.32 |
|
Amana Bank Ltd
CM:ABLN0000
|
$917.74 |
|
Tricida Inc
STU:1T7
|
$914.15 |
|
Raigam Wayamba Salterns PLC
CM:RWSLN0000
|
$913.71 |
|
VJTTY
PINK:VJTTY
|
$913.00 |
|
LOTTOTECH LTD
SEM:LOTO
|
$910.45 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Doseology Sciences Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,019,738 to 1,397,665, a change of 377,927 (37.1%).
- Net loss of 447,788 reduced equity.
- New share issuances of 730,624 increased equity.
- Other factors increased equity by 95,091.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-447.79K | -32.04% |
| Share Issuances | $730.62K | +52.27% |
| Other Changes | $95.09K | +6.8% |
| Total Change | $- | 37.06% |
Book Value vs Market Value Analysis
This analysis compares Doseology Sciences Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.53x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.36x to 0.53x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-06-30 | $0.26 | $0.10 | x |
| 2021-06-30 | $0.06 | $0.10 | x |
| 2022-06-30 | $0.08 | $0.10 | x |
| 2023-06-30 | $0.03 | $0.10 | x |
| 2024-06-30 | $0.23 | $0.10 | x |
| 2025-06-30 | $0.18 | $0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Doseology Sciences Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1052.23%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.07x
- Recent ROE (-32.04%) is above the historical average (-61.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -40.30% | 0.00% | 0.00x | 1.08x | $-538.73K |
| 2021 | -63.13% | 0.00% | 0.00x | 2.32x | $-1.88 Million |
| 2022 | -64.69% | -12084.50% | 0.00x | 1.29x | $-2.24 Million |
| 2023 | -137.08% | -4134.66% | 0.03x | 1.08x | $-1.91 Million |
| 2024 | -33.33% | -344.95% | 0.09x | 1.08x | $-441.82K |
| 2025 | -32.04% | -1052.23% | 0.03x | 1.07x | $-587.55K |
Industry Comparison
This section compares Doseology Sciences Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Doseology Sciences Inc. (DOSEF) | $1.69 Million | -40.30% | 0.06x | $914.19 |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |